Jain Nimesh, Yadav Naresh Kumar, Jayadev Chaitra, Srinivasan Priya, Mohan Ashwin, Shetty Bhujang K
Vitreo-Retina Department, Narayana Nethralaya, Bangalore, India.
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):488-492. doi: 10.22608/APO.2017125. Epub 2017 Oct 23.
The aim of our study was to share our experience with anti-vascular endothelial growth factor (anti-VEGF) injections in the treatment of neovascular age-related macular degeneration (nAMD) in a real-world setting.
A retrospective, observational study.
Patients of Indian origin with nAMD receiving anti-VEGF with a minimum follow-up of 12 months were enrolled in this study. In group 1, patients were treated on a pro re nata (PRN) basis; in group 2, patients received a loading dose (3 injecti Results: Overall, we observed that 77.31% (92/119 eyes) of patients either maintained or had improved visual acuity at 12 months' follow-up. Similar visual outcome was observed in both groups. The average number of injections given in group 1 was 4.98 and in group 2 was 3.7. CDVA at 12 months was significantly correlated with type of drug molecule, CSFT at 3 and 12 months, baseline visual acuity, and CDVA at 3 months.
PRN treatment with significantly fewer injections achieved similar anatomical and functional outcomes when compared with the loading dose group. The results of this study need to be validated with a larger study group and a longer follow-up.
我们研究的目的是分享在真实世界环境中使用抗血管内皮生长因子（anti-VEGF）注射治疗新生血管性年龄相关性黄斑变性（nAMD）的经验。
一项回顾性观察研究。
纳入印度裔nAMD患者，接受anti-VEGF治疗且随访至少12个月。在第1组中，患者按需（PRN）治疗；在第2组中，患者接受负荷剂量（3次注射……结果：总体而言，我们观察到77.31%（92/119只眼）的患者在12个月随访时视力维持或提高。两组观察到相似的视力结果。第1组平均注射次数为4.98次，第2组为3.7次。12个月时的矫正视力与药物分子类型、3个月和12个月时的中心凹下视网膜厚度、基线视力以及3个月时的矫正视力显著相关。
与负荷剂量组相比，按需治疗注射次数显著减少，但取得了相似的解剖和功能结果。本研究结果需要在更大的研究组和更长的随访中进行验证。
